Glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet. Credit: Novo Nordisk A/S.

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s oral semaglutide Rybelsus for the treatment of type 2 diabetes mellitus, alongside diet and exercise.

Oral semaglutide is a glucagon-like peptide-1 (GLP-1) analogue formulated as a tablet to improve glycaemic control in adult patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Intended for once-daily administration, Rybelsus secured approval for 7mg and 14mg doses. The drug is said to be the first oral GLP-1 therapy approved for type 2 diabetes.

FDA approval comes from results from ten PIONEER clinical trials conducted in a total of 9,543 adult type 2 diabetes patients. Data found Rybelsus to be more effective in lowering blood sugar compared to sitagliptin and empagliflozin.

Furthermore, the drug was observed to reduce up to 4.4kg in body weight and was also safe and well-tolerated in all trials. The most common adverse effect was mild to moderate nausea.

Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said: “We are very excited that we can make the first oral GLP-1 available in the US and thereby expand the treatment options for adults living with type 2 diabetes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Novo Nordisk has a very long legacy of developing innovative injectable medicines for people living with diabetes and with the approval of Rybelsus, we are now able to bring our innovation into the market for oral antidiabetics.”

The company plans to commercially launch the drug in the US in the fourth quarter of the year.

Rybelsus is also under review by regulatory agencies in other markets, including Europe and Japan.

The company is also seeking FDA approval for the use of the drug to mitigate adverse cardiovascular effects in adults with type 2 diabetes and cardiovascular disease. FDA is expected to provide its decision by the first quarter of next year.